Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2017
At a glance
- Drugs IMC CS4 (Primary)
- Indications Advanced breast cancer; Prostate cancer
- Focus Pharmacodynamics
- Sponsors Eli Lilly
- 12 Dec 2016 Planned number of patients changed from 16 to 36.
- 12 Dec 2016 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
- 12 Dec 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.